Document is current
Any future updates will be listed below
-
Authors
Bender, Catherine M. https://orcid.org/0000-0003-1205-9950
Sereika, Susan M.
Gentry, Amanda L.
Zhu, Yehui
Wagner, Monica
Cuglewski, Cheryl
Duquette, Jennie
Grove, George
Cummings, Meredith
Cho, Myeong-ga
Brufsky, Adam M.
Diego, Emilia J.
McAuliffe, Priscilla F.
Marsland, Anna L.
Conley, Yvette P.
Erickson, Kirk I.
-
Funding
Funding for this research was provided by:
National Cancer Institute, United States (R01-CA221882, R01-CA221882, R01-CA221882, R01-CA221882, R01-CA221882, R01-CA221882, R01-CA221882, R01-CA221882)
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 9 February 2025
First Online: 4 March 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Boards of the University of Pittsburgh (Approval #19080223) and St. Clair Health (Approval #1712001).
: All participants provided written informed consent upon study enrollment.
: Adam Brufsky, Md, PhD has the following disclosures: •Consultant: Astrazeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad •Research Support: Agendia, Astrazeneca Kirk Erickson, PhD has the following disclosures: •Member of scientific advisory boards for MedRhythms, Inc. and NeoAuvra, Inc. There are no other author conflicts to declare.
: Adam Brufsky, Md, PhD, has the following disclosures:• Consultant: Astrazeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, Myriad.• Research Support: Agendia, Astrazeneca.Kirk Erickson, PhD, has the following disclosures:• Member of scientific advisory boards for MedRhythms, Inc., and NeoAuvra, Inc.There are no other author conflicts to declare.
: Clinical Trials.gov (NCT 02793921).
